Morinaga Nutritional Foods Vietnam (MNFV), Is Strengthening Its Efforts To Respect Human Rights And Human Capital Developmentby October 31, 2024PR Newswire
Haier Mix Pro14 Ultrabook: A Perfect Blend of Performance and Portabilityby October 31, 2024PR Newswire
NTT Sparks Collaboration on AI, Drives Smart City Development at Innovation Summitby October 31, 2024PR Newswire
Global Times: 15 years on, China’s Nasdaq-style ChiNext board drives innovative economic growthby October 31, 2024PR Newswire
Louvre Abu Dhabi ได้เปิดตัวโครงการทุนการศึกษาและทุนสนับสนุนสำหรับนักวิชาการจากทั่วโลกby October 31, 2024PR Newswire
Formnext’s South China event to rebrand as Formnext Asia Shenzhen in 2025, reflecting wider reach across Asiaby October 31, 2024PR Newswire
e& เผยผลประกอบการประจำไตรมาส 3 ปี 2567 รายรับรวมเติบโต 10% อยู่ที่ 1.44 หมื่นล้านดีแรห์มby October 31, 2024PR Newswire
Astronergy เรียกร้องให้มีการลงมือเพื่ออนาคตยั่งยืนด้วยแคมเปญ “Solar Together, For A Green World”by October 31, 2024PR Newswire
Taiwan’s Fintech Shines in Singapore! FinTechSpace Once Again Leads a Delegation to 2024 Singapore FinTech Festivalby October 31, 2024PR Newswire
ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs)by October 31, 2024PR Newswire
CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UKby October 31, 2024PR Newswire
EQT Acquires Leading SaaS Talent Solutions Provider PageUp to Accelerate Global Expansion and Product Innovationby October 31, 2024PR Newswire
Breakthrough Australian Cancer trial: retraining immune cells offers new hope for patientsby October 31, 2024PR Newswire
Toshiba and Naturenix Launch Demonstration Test of Battery Subscription Service for Electric Motorcycle Taxis in Bangkokby October 31, 2024PR Newswire
Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLCby October 31, 2024PR Newswire
Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLCby October 31, 2024PR Newswire
